We are live on ! Find out more

FPRX

Five Prime Therapeutics, Inc.

FPRX

Delisted

FPRX was delisted on the 15th of April, 2021.

71 hedge funds and large institutions have $369M invested in Five Prime Therapeutics, Inc. in 2014 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 26 increasing their positions, 15 reducing their positions, and 8 closing their positions.

New

Increased

Maintained

Reduced

Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

157% more capital invested

Capital invested by funds: $144M → $369M (+$226M)

125% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 8

73% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 15

13% more funds holding

Funds holding: 63 → 71 (+8)

Holders

Holders Change

Holders Change %

+12.7%

% of All Funds

1.89%

Holding in Top 10

Holding in Top 10 Change

Holding in Top 10 Change %

+200%

% of All Funds

0.08%

New

Increased

Reduced

Closed

Calls

–

Puts

–

Net Calls

–

Net Calls Change

–

Top Buyers

1	Point72 Asset Management Stamford, Connecticut	+$9.77M
2	Adage Capital Partners Boston, Massachusetts	+$7.23M
3	BFA BlackRock Fund Advisors San Francisco, California	+$5.45M
4	BIM Bogle Investment Management Newton Lower Falls, Massachusetts	+$3.12M
5	T. Rowe Price Associates Baltimore, Maryland	+$2.87M

Top Sellers

1	O OrbiMed New York	-$12.6M
2	BI BVF Inc San Francisco, California	-$10.9M
3	Goldman Sachs New York	-$7.98M
4	QF QVT Financial New York	-$2.54M
5	NI Numeric Investors Boston, Massachusetts	-$540K

#	Name	Holding	Trade Value	Shares Change	Change in Stake
51	51 Citigroup New York	$386K	+$118K	+6,867	+92%
52	MLICM 52 Metropolitan Life Insurance Company (MetLife) New York	$381K	–	–	–
53	53 RhumbLine Advisers Boston, Massachusetts	$378K	+$20.4K	+1,185	+9%
54	TAM 54 Tocqueville Asset Management New York	$357K	+$34.4K	+2,000	+18%
55	55 VOYA Investment Management Atlanta, Georgia	$343K	–	–	–
56	BG 56 BlackRock Group London, United Kingdom	$322K	+$205K	+11,935	New
57	57 State Board of Administration of Florida Retirement System Tallahassee, Florida	$305K	–	–	–
58	58 PNC Financial Services Group Pittsburgh, Pennsylvania	$298K	-$2.07K	-120	-1%
59	AIG 59 American International Group New York	$293K	-$7.4K	-430	-4%
60	60 Goldman Sachs New York	$284K	-$7.98M	-463,852	-98%
61	CSS 61 Cubist Systematic Strategies Stamford, Connecticut	$260K	+$166K	+9,647	New
62	62 Morgan Stanley New York	$184K	-$277K	-16,107	-70%
63	63 Legal & General Group London, United Kingdom	$90K	–	–	–
64	64 Bank of America Charlotte, North Carolina	$57K	-$15.2K	-885	-30%
65	BJ 65 BlackRock Japan Tokyo, Japan	$56K	+$35.6K	+2,068	New
66	66 AllianceBernstein Nashville, Tennessee	$32K	–	–	–
67	67 Barclays London, United Kingdom	$27K	+$7.16K	+416	+73%
68	TRCT 68 Tower Research Capital (TRC) New York	$22K	+$7.63K	+443	+116%
69	69 Fifth Third Bancorp Cincinnati, Ohio	$14K	+$8.61K	+500	New
70	70 BlackRock New York	$12K	–	–	–
71	71 Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada	$306	+$11.1K	+643	+6%
72	O 72 OrbiMed New York	–	-$12.6M	-1,075,400	Closed
73	NI 73 Numeric Investors Boston, Massachusetts	–	-$540K	-46,049	Closed
74	ROTUOC 74 Regents of the University of California Oakland, California	–	-$261K	-22,214	Closed
75	75 JP Morgan Chase New York	–	-$197K	-16,791	Closed

FPRX Hedge Fund Activity: Q4 2014 in Review

71 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q4 2014, worth a combined $369M — up 157% from $144M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new FPRX positions and 8 closed out — a net gain of 10 holders — while 26 added to existing stakes and 15 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $9.77M. The largest seller was OrbiMed, exiting entirely with an estimated $12.6M sold.

71 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q4 2014, up from 63 in Q3 2014.
Funds reported $369M of Five Prime Therapeutics, Inc. stock for Q4 2014, up 157% quarter-over-quarter.
18 funds opened new Five Prime Therapeutics, Inc. positions in Q4 2014 and 8 closed out, a net change of +10 holders.
The largest Five Prime Therapeutics, Inc. buyer in Q4 2014 was Point72 Asset Management, an estimated $9.77M added.
The largest Five Prime Therapeutics, Inc. seller in Q4 2014 was OrbiMed, an estimated $12.6M sold.

Based on aggregated 13F filings for Q4 2014.

Five Prime Therapeutics, Inc. FPRX